Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) CFO Alexis Desieno sold 8,854 shares of the stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $3.67, for a total transaction of $32,494.18. Following the transaction, the chief financial officer now directly owns 121,976 shares in the company, valued at $447,651.92. This trade represents a 6.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Alexis Desieno also recently made the following trade(s):
- On Friday, November 15th, Alexis Desieno sold 25,118 shares of Cardlytics stock. The shares were sold at an average price of $3.43, for a total transaction of $86,154.74.
Cardlytics Price Performance
Shares of CDLX stock traded down $0.32 during trading on Monday, hitting $3.49. The company had a trading volume of 2,033,344 shares, compared to its average volume of 1,212,448. The stock has a market capitalization of $177.37 million, a price-to-earnings ratio of -0.57 and a beta of 1.53. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40. Cardlytics, Inc. has a 52 week low of $2.89 and a 52 week high of $20.52. The stock’s 50-day moving average is $3.93 and its two-hundred day moving average is $4.85.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of CDLX. Atom Investors LP purchased a new stake in Cardlytics during the 3rd quarter valued at $33,000. XTX Topco Ltd purchased a new stake in Cardlytics in the 2nd quarter worth $107,000. SG Americas Securities LLC bought a new position in shares of Cardlytics during the 3rd quarter valued at approximately $45,000. Intech Investment Management LLC purchased a new position in Cardlytics in the third quarter worth about $47,000. Finally, Quest Partners LLC raised its stake in shares of Cardlytics by 160.4% in the second quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock valued at $147,000 after acquiring an additional 11,061 shares during the period. 68.10% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on CDLX shares. Evercore ISI began coverage on Cardlytics in a research report on Friday, October 11th. They issued an “in-line” rating and a $4.00 price target for the company. Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. Finally, Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $6.92.
Get Our Latest Stock Report on CDLX
Cardlytics Company Profile
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Featured Articles
- Five stocks we like better than Cardlytics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- What Are Dividend Champions? How to Invest in the Champions
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- How to invest in marijuana stocks in 7 stepsĀ
- How Cigna Remains at the Top of the Health Insurance Food Chain
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.